Simvastatin gehört zu den Statinen – Cholesterinsenkern, die zu den wichtigsten Medikamenten in der Herz-Kreislauf-Prävention zählen. Es senkt das LDL-Cholesterin, stabilisiert Gefäßplaques und reduziert nachweislich Herzinfarkte und Schlaganfälle.
Doch Simvastatin hat eine Besonderheit, die es von anderen Statinen unterscheidet: Es wird stark über das Leberenzym CYP3A4 abgebaut – und genau dieses Enzym wird von vielen anderen Medikamenten blockiert. Allen voran Amlodipin: Die häufigste und am meisten übersehene Wechselwirkung in deutschen Apotheken.
.gif)
Simvastatin is a prescription medication. Never stop on your own initiative — the cardiovascular protection is vital in the long term.
Simvastatin is one of the most widely prescribed medications worldwide and has been a cornerstone of cardiovascular prevention for decades. It belongs to the class of statins — cholesterol-lowering agents that not only reduce LDL levels but also directly protect the vessel wall through so-called pleiotropic effects. Simvastatin has several pharmacological features that distinguish it from newer statins: a short half-life (evening intake is essential), pronounced CYP3A4 dependence (many interactions), and a clinically critical dose restriction when used alongside amlodipine.
| Property | Details |
|---|---|
| Active substance | Simvastatin |
| ATC code | C10AA01 |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Available forms | Tablets 10 mg, 20 mg, 40 mg, 80 mg |
| Half-life | 1–3 hours (active metabolites longer) |
| Bioavailability | approx. 5% (extensive first-pass metabolism!) |
| Metabolism | CYP3A4 (very pronounced — reason for many interactions) |
| Timing | EVENING (due to nocturnal cholesterol synthesis) |
| Prescription only | Yes |
| Special feature | Prodrug — converted to active metabolite in the liver |
Simvastatin inhibits the enzyme HMG-CoA reductase in the liver — the rate-limiting step in endogenous cholesterol production. When the liver produces less cholesterol, it responds with a compensatory mechanism: it forms more LDL receptors on its cell surface and takes up more LDL cholesterol from the blood. LDL levels in the blood fall.
Beyond this direct effect, statins have so-called pleiotropic effects: they stabilise vulnerable atherosclerotic plaques (reducing the risk of acute myocardial infarction), exert anti-inflammatory effects in the vessel wall, and improve endothelial function. These effects explain why statins can be life-extending even with only modestly elevated cholesterol.
This is due to the circadian rhythm of cholesterol synthesis: HMG-CoA reductase is most active in the late evening and at night — the period during which the liver produces most of its daily cholesterol. Simvastatin has a short half-life of only 1–3 hours. If taken in the morning, the active substance has largely been cleared by the evening — exactly when the liver is producing cholesterol at full speed. Evening intake ensures simvastatin is present at precisely the right time. This is an important difference from atorvastatin and rosuvastatin, which have long half-lives and can be taken at any time of day.
| Dose | LDL reduction (approx.) | Note |
|---|---|---|
| 10 mg | 27% | Starting dose, e.g. in older patients or those at risk of interactions |
| 20 mg | 32% | Standard dose when co-prescribed with amlodipine |
| 40 mg | 37% | Standard dose without CYP3A4 interactions |
| 80 mg | 42% | Only in patients stable on this dose for >1 year. Not recommended for new starts (MHRA/FDA 2011)! |
This is the most clinically important and most frequently overlooked interaction in simvastatin therapy. It was named "Drug Interaction of the Year" in 2015 — and is still regularly missed in everyday clinical practice.
The problem in practice: amlodipine and simvastatin are both common cardiovascular medications frequently prescribed together. Many patients have been taking amlodipine 10 mg and simvastatin 40 mg for years — without the dose restriction having been observed. brite's interaction check detects this combination automatically.
If 20 mg simvastatin is insufficient and amlodipine is to be continued, the solution is not to increase the simvastatin dose — it is to switch to a different statin. Atorvastatin is only minimally affected by CYP3A4 (no relevant dose limit under amlodipine); rosuvastatin is not metabolised via CYP3A4 at all. Check all combinations with the interaction check.
The amlodipine trap is only the most well-known of several clinically relevant dose restrictions. All arise from the same mechanism: inhibition of CYP3A4, the enzyme that metabolises simvastatin.
| Co-medication | Max. simvastatin dose | Reason |
|---|---|---|
| Amlodipine | 20 mg/day | CYP3A4 inhibition → simvastatin levels +80% |
| Verapamil | 10 mg/day | Strong CYP3A4 inhibition |
| Diltiazem | 10 mg/day | Strong CYP3A4 inhibition |
| Amiodarone | 20 mg/day | CYP3A4 inhibition |
| Ranolazine | 20 mg/day | CYP3A4 inhibition |
| Grapefruit juice | Avoid completely! | Massively inhibits intestinal CYP3A4 |
| Ciclosporin | Contraindicated | Extremely elevated myopathy risk |
| Gemfibrozil | Contraindicated | Elevated rhabdomyolysis risk |
| Clarithromycin / erythromycin | Contraindicated (during antibiotic course) | Strong CYP3A4 inhibition → pause simvastatin! |
| Ketoconazole / itraconazole | Contraindicated (during course) | Strong CYP3A4 inhibition → pause simvastatin! |
Muscle pain is the best-known side effect of all statins — and the most common reason for stopping therapy. The clinically decisive question is whether the pain represents a harmless myalgia or a serious muscle injury. The difference: the CK value in the blood.
| Myalgia (harmless) | Myopathy (serious) | Rhabdomyolysis (emergency!) | |
|---|---|---|---|
| Frequency | 5–10% of all statin users | <0.1% | <0.01% |
| Symptoms | Muscle pain, stiffness, weakness — WITHOUT raised CK | Muscle pain + CK >10× elevated | Extreme muscle breakdown, dark brown urine, kidney failure |
| CK value | Normal | >10× upper limit of normal | Massively elevated (often >40×) |
| What to do | Inform doctor. Measure CK. Consider switching to different statin | Stop simvastatin immediately! Monitor CK and kidney values |
An important scientific finding that many patients are unaware of: in controlled trials (SAMSON trial, StatinWISE) patients report similarly frequent muscle pains under statin and under placebo — when they do not know which they are taking. When patients know they are taking a statin, complaints increase through the nocebo effect (negative expectation). This does not mean statin-related muscle pain is imaginary — genuine myopathy exists. But it does mean a CK value should be measured before stopping the statin. With a normal CK, re-challenge (another trial with the same or a lower dose) or switching to a different statin (rosuvastatin, pravastatin) is worthwhile.
Apart from muscle pain, simvastatin has a manageable side effect profile. Two points deserve particular attention: the mildly elevated diabetes risk (a class effect of all statins) and sleep disturbances due to simvastatin's lipophilicity.
| Side effect | Frequency | Note |
|---|---|---|
| Headaches | Common | Usually transient |
| Gastrointestinal complaints | Common | Constipation, bloating, nausea |
| Elevated liver enzymes (transaminases) | Occasional | Check at start of therapy and if symptoms occur. Usually reversible |
| Elevated diabetes risk | Occasional (class effect) | approx. 9–12% increased T2DM risk — but cardiovascular benefit clearly outweighs! |
| Sleep disturbances | Occasional | Simvastatin is lipophilic and crosses the blood-brain barrier |
| Hepatitis | Very rare | With jaundice or dark urine: stop immediately and see a doctor |
The diabetes risk: studies show an approximately 9–12% increased risk of type 2 diabetes under statin therapy. This sounds concerning — but in context it is clearly put in perspective: for every 255 patients taking a statin for 4 years, 1 additional diabetes case arises, but simultaneously 5.4 cardiovascular events (heart attacks, strokes) are prevented. The benefit-risk ratio is unambiguously positive.
Beyond the dose-restricting CYP3A4 inhibitors from chapter 5, there are further relevant interactions. Check all combinations with the interaction check.
| Substance / medication | Interaction | Recommendation |
|---|---|---|
| Grapefruit juice | Massively inhibits intestinal CYP3A4 → simvastatin levels rise substantially | Avoid grapefruit and pomelo entirely. Oranges and lemons are safe. |
| St John's Wort | Induces CYP3A4 → simvastatin levels fall → loss of effect | Avoid combination |
| Warfarin | Simvastatin can enhance the anticoagulant effect | Monitor INR at start of therapy and after dose changes |
| Fibrates (other than gemfibrozil) | Elevated myopathy risk | Use with caution; monitor CK |
| Colchicine | Elevated myopathy risk | Avoid combination in renal impairment |
Simvastatin, atorvastatin, and rosuvastatin are all lipid-lowering statins — but with considerably different pharmacological profiles. The comparison shows why atorvastatin and rosuvastatin are increasingly preferred in modern therapy.
| Property | Simvastatin | Atorvastatin | Rosuvastatin |
|---|---|---|---|
| LDL reduction (max. dose) | approx. 42% (80 mg) | approx. 55% (80 mg) | approx. 55% (40 mg) |
| Timing | EVENING (short half-life) | Any time (long half-life) | Any time (long half-life) |
| CYP3A4-dependent | Yes — strongly | Partially | No |
| Amlodipine interaction | Yes — max. 20 mg! | Minimal (no dose limit) | None |
| Grapefruit interaction | Yes — avoid completely | Minimal | None |
| Lipophilic/hydrophilic | Lipophilic (more CNS side effects) | Lipophilic | Hydrophilic (fewer CNS side effects) |
| Approx. cost (30 days, generic) | £1–3 | £2–4 | £2–5 |
In older patients, statins are both appropriate and safe — but the interaction risk through polypharmacy is increased. With multiple concurrent medications, switching to rosuvastatin or pravastatin (fewer CYP interactions) may be appropriate. In severe liver disease: contraindicated. In severe renal impairment (eGFR below 30): dose with caution, maximum 10 mg. Check liver enzymes before starting therapy and if symptoms occur.
| Observation | Frequency | Typical comment |
|---|---|---|
| Simvastatin + amlodipine above dose limit | Very common | "The app warned me that my simvastatin dose was too high with amlodipine. My doctor wasn't aware." |
| Muscle pain reported | Common | "My thighs have been aching since I started the statin. The app advised me to have CK measured." |
| Morning instead of evening intake | Common | "I was taking simvastatin in the morning — the app flagged the evening timing." |
| Grapefruit juice interaction unknown | Occasional | "I drink grapefruit juice every morning — nobody had told me about this." |
| Self-discontinuation due to muscle pain | Occasional | "I just stopped the statin. The app explained why that's dangerous." |
Simvastatin evening — why, and what happens if I take it in the morning? The answer is pharmacologically precise: the liver produces most of its cholesterol at night, and HMG-CoA reductase peaks in the late evening hours. Simvastatin has a half-life of 1–3 hours. Anyone who takes it in the morning has barely any active substance in the blood by evening — precisely when it is needed. The loss of efficacy from morning intake is clinically measurable. Atorvastatin and rosuvastatin (long half-life) do not have this problem.
Simvastatin amlodipine maximum dose — why only 20 mg? Amlodipine inhibits CYP3A4 — the enzyme that metabolises simvastatin in the liver. With simvastatin levels 80% higher, the risk of muscle damage (myopathy, rhabdomyolysis) rises substantially. The MHRA and FDA issued an explicit warning in 2011 setting a maximum of 20 mg under amlodipine. If stronger LDL reduction is needed: discuss switching to atorvastatin or rosuvastatin.
Simvastatin muscle pain dangerous — should I stop immediately? Not necessarily and not without measuring CK first. See the doctor and have CK measured. With normal CK: muscle pain is probably not myopathy (possibly nocebo effect). Options: switch to different statin, dose reduction, intermittent dosing. With strongly elevated CK (more than 10-fold): stop immediately. With suspected rhabdomyolysis (dark brown urine): go to A&E.
Simvastatin 80 mg not recommended — why? The SEARCH trial showed a substantially elevated myopathy risk at 80 mg simvastatin. The MHRA and FDA have recommended since 2011: no new starts at 80 mg. Patients already stably on 80 mg for over a year may continue. For all others: if 40 mg is insufficient, switching to atorvastatin (stronger LDL reduction, safer) is the right decision.
Grapefruit simvastatin — which fruits are affected? Only grapefruit and pomelo — not other citrus fruits. Grapefruit juice inhibits intestinal CYP3A4 and substantially raises simvastatin bioavailability. Oranges, lemons, limes, mandarins, and clementines are all safe. A time gap between grapefruit and simvastatin barely helps — the CYP3A4 inhibitory effect persists for up to 24 hours. With simvastatin: avoid grapefruit and pomelo entirely.